Search

Your search keyword '"Hreinsson, Johann P."' showing total 155 results
Start Over Author "Hreinsson, Johann P." Publication Year Range Last 10 years
155 results on '"Hreinsson, Johann P."'

6. Sex Differences, Menses‐Related Symptoms and Menopause in Disorders of Gut–Brain Interaction.

Author

Sarnoff, Rachel P., Hreinsson, Johann P., Kim, Joanna, Sperber, Ami D., Palsson, Olafur S., Bangdiwala, Shrikant I., and Chang, Lin

Subjects
*SEX factors in disease, *IRRITABLE colon, *SEX hormones, *VISCERAL pain, *POSTMENOPAUSE
Abstract

ABSTRACT Background Methods Key Results Conclusions and Inferences Disorders of gut–brain interaction (DGBI) predominate in women, but little is known about sex differences in menses‐related or menopause symptoms.Using data from the Rome Foundation Global Epidemiology Survey, we assessed Rome IV DGBI symptoms in individuals in 26 countries who met criteria for ≥ 1 of 5 DGBI: irritable bowel syndrome (IBS), functional dyspepsia (FD), functional constipation (FC), functional diarrhea (FDr), or functional bloating (FB). Participants included pre‐ and post‐menopausal women with DGBI and age‐matched men. Odds ratios estimated sex and age differences for symptom by sex or pre‐ vs. post‐menopause in logistic regression; standardized mean difference (SMD) provided effect sizes.14,570 participants met criteria for ≥ 1 of the 5 DGBI. Women exceeded men in most symptoms. In FD, women stopped eating due to early satiety more than men (11.1 vs. 8.9 days/month, SMD 0.21). Symptoms were generally increased in premenopausal women and younger men compared to older counterparts; however, only premenopausal IBS, FD, and FC women reported increased constipation‐associated symptoms. Compared to premenopausal women, postmenopausal women had increased accidental stool leakage in IBS and FDr, and increased digital manual maneuvers in FC (18% vs. 25% frequency, SMD −0.25). IBS and FD had the most menses‐associated symptoms.Women had higher symptom frequency across the 5 DGBI compared to men. Our findings suggest that premenopausal women have greater visceral perception than postmenopausal women, although increased outlet symptoms in postmenopausal women indicate greater anorectal/pelvic dysfunction. While age alone has some influence on symptoms, female sex hormones may also increase visceral perception. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

9. Reply

Author

Ingason, Arnar B., primary, Hreinsson, Johann P., additional, and Bjornsson, Einar S., additional

Published
2023
Full Text
View/download PDF

10. Face‐to‐face interviews versus Internet surveys: Comparison of two data collection methods in the Rome foundation global epidemiology study: Implications for population‐based research

Author

Sperber, Ami D., primary, Bor, Serhat, additional, Fang, Xuicai, additional, Bangdiwala, Shrikant I., additional, Drossman, Douglas A., additional, Ghoshal, Uday C., additional, Simren, Magnus, additional, Tack, Jan, additional, Whitehead, William E., additional, Dumitrascu, Dan L., additional, Fukudo, Shin, additional, Kellow, John, additional, Okeke, Edith, additional, Quigley, Eamonn M. M., additional, Schmulson, Max, additional, Whorwell, Peter, additional, Archampong, Timothy, additional, Adibi, Payman, additional, Andresen, Viola, additional, Benninga, Marc A., additional, Bonaz, Bruno, additional, Fernandez, Luis Bustos, additional, Choi, Suck Chei, additional, Corazziari, Enrico S., additional, Francisconi, Carlos, additional, Hani, Albis, additional, Lazebnik, Leonid, additional, Lee, Yeong Yeh, additional, Mulak, Agata, additional, Rahman, M. Masudur, additional, Santos, Javier, additional, Setshedi, Mashiko, additional, Syam, Ari Fahrial, additional, Vanner, Stephen, additional, Wong, Reuben K., additional, Lopez‐Colombo, Aurelio, additional, Costa, Valeria, additional, Dickman, Ram, additional, Kanazawa, Motoyori, additional, Keshteli, Ammar Hassanzadeh, additional, Khatun, Rutaba, additional, Maleki, Iradj, additional, Poitras, Pierre, additional, Pratap, Nitesh, additional, Stefanyuk, Oksana, additional, Thomson, Sandie, additional, Buyruk, Murat, additional, Unal, Nalan, additional, Huang, Dan, additional, Song, Jun, additional, Hreinsson, Johann P., additional, and Palsson, Olafur S., additional

Published
2023
Full Text
View/download PDF

11. Randomised clinical trial and meta‐analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms and rectal biomarkers of immune activity

Author

Castro Tejera, Valeria, primary, Öhman, Lena, additional, Aabakken, Lars, additional, Fellström, Bengt, additional, Hausken, Trygve, additional, Hovde, Øistein, additional, Hreinsson, Johann P., additional, Lindberg, Greger, additional, Venge, Per, additional, Simrén, Magnus, additional, and Törnblom, Hans, additional

Published
2022
Full Text
View/download PDF

12. A comparative study of disorders of gut–brain interaction in Western Europe and Asia based on the Rome foundation global epidemiology study.

Author

Hreinsson, Johann P., Wong, Reuben K. M., Tack, Jan, Whorwell, Peter, Benninga, Marc A., Andresen, Viola, Bonaz, Bruno, Choi, Suck Chei, Corazziari, Enrico S., Santos, Javier, Fukudo, Shin, Kanazawa, Motoyori, Fang, Xuicai, Bangdiwala, Shrikant I., Sperber, Ami D., Palsson, Olafur S., and Simrén, Magnus

Subjects
*PSYCHOLOGICAL adaptation, *COMPARATIVE studies, *ODDS ratio
Abstract

Objective: Many studies have been published on disorders of the gut–brain interaction (DGBI) in Asia and Western Europe, but no previous study has directly assessed the difference between the two regions. The aim was to compare the prevalence of DGBI in Asia and Western Europe. Methods: We used data collected in a population‐based Internet survey, the Rome Foundation Global Epidemiology Study, from countries in Western Europe (Belgium, France, Germany, Netherlands, Italy, Spain, Sweden, and the United Kingdom) and Asia (China, Japan, South Korea, and Singapore). We assessed DGBI diagnoses (Rome IV Adult Diagnostic Questionnaire), anxiety/depression (Patient Health Questionnaire‐4, PHQ‐4), non‐GI somatic symptoms (PHQ‐12), and access to and personal costs of doctor visits. Results: The study included 9487 subjects in Asia and 16,314 in Western Europe. Overall, 38.0% had at least one DGBI; younger age, female sex, and higher scores on PHQ4 and PHQ12 were all associated with DGBI. The prevalence of having at least one DGBI was higher in Western Europe than in Asia (39.1% vs 36.1%, OR 1.14 [95% CI 1.08–1.20]). This difference was also observed for DGBI by anatomical regions, most prominently esophageal DGBI (OR 1.67 [1.48–1.88]). After adjustment, the difference in DGBI prevalence diminished and psychological (PHQ‐4) and non‐GI somatic symptoms (PHQ‐12) had the greatest effect on the odds ratio estimates. Conclusion: The prevalence of DGBI is generally higher in Western Europe compared to Asia. A considerable portion of the observed difference in prevalence rates seems to be explained by more severe psychological and non‐GI somatic symptoms in Western Europe. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Mo1425: COMORBID DISORDERS OF GUT-BRAIN INTERACTIONS IN INDIVIDUALS WITH SEVERE PSYCHOLOGICAL DISTRESS AND SOMATIC SYMPTOMS: RESULTS FROM A GLOBAL EPIDEMIOLOGY INTERNET STUDY

Author

Trindade, Inês A., primary, Hreinsson, Johann P., additional, Melchior, Chloé, additional, Algera, Joost P., additional, Colomier, Esther, additional, Törnblom, Hans, additional, Drossman, Douglas A., additional, Tack, Jan F., additional, Palsson, Olafur S., additional, Bangdiwala, Shrikant I., additional, Sperber, Ami D., additional, and Simren, Magnus, additional

Published
2022
Full Text
View/download PDF

26. Randomised clinical trial and meta-analysis : mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.

Author

Castro Tejera, Valeria, Öhman, Lena, Aabakken, Lars, Fellström, Bengt, Hausken, Trygve, Hovde, Øistein, Hreinsson, Johann P, Lindberg, Greger, Venge, Per, Simrén, Magnus, Törnblom, Hans, Castro Tejera, Valeria, Öhman, Lena, Aabakken, Lars, Fellström, Bengt, Hausken, Trygve, Hovde, Øistein, Hreinsson, Johann P, Lindberg, Greger, Venge, Per, Simrén, Magnus, and Törnblom, Hans

Abstract

BACKGROUND: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS). AIMS: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in subjects with IBS (Rome III criteria), with an eight-week treatment period of mesalazine 2400 mg or plcebo once-daily. The primary endpoint was the global assessment of satisfactory relief of IBS symptoms in ≥50% of weeks during intervention. IBS symptoms were also measured with the IBS severity scoring system; immune activity was measured by mucosal patch technology. A post hoc meta-analysis of randomised placebo-controlled trials of mesalazine in IBS was added. RESULTS: Of 181 included patients, 91 received mesalazine and 90 received placebo. The primary endpoint was met by 32 (36%) patients after mesalazine and 27 (30%) after placebo (p = 0.40). There were no differences in response rates related to IBS subtype or post-infection symptom onset. More reduction of abdominal bloating was noted in the mesalazine group (p = 0.02). The meta-analysis showed no effect of mesalazine on IBS symptoms. No mucosal patch technology measure could predict response to mesalazine, and found no differences in the effects of intervention on levels of immune markers. CONCLUSIONS: Mesalazine is ineffective in reducing IBS symptoms. Rectal measures of immune activity by the mucosal patch technology cannot predict a higher chance of response to mesalazine.

Published
2022
Full Text
View/download PDF

27. Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score‐weighted study

Author

Ingason, Arnar B., primary, Rumba, Edward, additional, Hreinsson, Johann P., additional, Agustsson, Arnar S., additional, Lund, Sigrun H., additional, Palsson, Daniel A., additional, Reynisson, Indridi E., additional, Gudmundsdottir, Brynja R., additional, Onundarson, Pall T., additional, Tryggvason, Geir, additional, and Bjornsson, Einar S., additional

Published
2022
Full Text
View/download PDF

31. Tu1624 EFFECTS OF CHANGES IN THE DIAGNOSTIC CRITERIA FOR IRRITABLE BOWEL SYNDROME (IBS) ON GLOBAL PREVALENCE RATES-RESULTS FROM THE ROME FOUNDATION GLOBAL EPIDEMIOLOGY STUDY

Author

Tornkvist, Navkiran Thind, Palsson, Olafur S., Hreinsson, Johann P., Törnblom, Hans, Cash, Brooks D., Corsetti, Maura, Hou, Xiaohua, Lacy, Brian E., Lembo, Anthony, Wasserman, Max J. Schmulson, Shin, Andrea S., Bangdiwala, Shrikant I., Sperber, Ami D., and Simren, Magnus

Published
2023
Full Text
View/download PDF

33. Mo1107 A COMPARATIVE STUDY OF DISORDERS OF GUT-BRAIN INTERACTION IN WESTERN EUROPE AND ASIA BASED ON THE ROME FOUNDATION GLOBAL EPIDEMIOLOGY STUDY

Author

Hreinsson, Johann P., Wong, Reuben K., Tack, Jan F., Whorwell, Peter J., Benninga, Marc A., Andresen, Viola, Bonaz, Bruno L., Choi, Suck Chei, Corazziari, Enrico, Santos, Javier, Fukudo, Shin, Kanazawa, Motoyori, Fang, Xiucai, Bangdiwala, Shrikant I., Sperber, Ami D., Palsson, Olafur S., and Simren, Magnus

Published
2023
Full Text
View/download PDF

38. 339 WARFARIN IS ASSOCIATED WITH HIGHER RATES OF UPPER BUT NOT LOWER GASTROINTESTINAL BLEEDING COMPARED TO DIRECT ORAL ANTICOAGULANTS: A POPULATION-BASED PROPENSITY SCORE MATCHED COHORT STUDY

Author

Ingason, Arnar B., primary, Hreinsson, Johann P., additional, Agustsson, Arnar S, additional, Lund, Sigrun H., additional, Reynisson, Indridi E., additional, Gudmundsdottir, Brynja R., additional, Onundarson, Pall T., additional, and Bjornsson, Einar, additional

Published
2020
Full Text
View/download PDF

45. Acute upper gastrointestinal bleeding: a population-based, five-year follow-up study.

Author

Hreinsson, Johann P., Jonsson, Armann, and Bjornsson, Einar S.

Subjects
*GASTROINTESTINAL hemorrhage, *COFFEE grounds, *PUBLIC hospitals, *HOSPITAL patients, *UNIVERSITY hospitals
Abstract

Data on long-term rebleeding risk and mortality in acute upper gastrointestinal bleeding (AUGIB) patients are scarce and comparison to controls are lacking. Aimsof the study were to assess long-term prognosis of AUGIB patients and compare to controls. A population-based retrospective case-control study conducted at the National University Hospital of Iceland and included all patients who underwent endoscopy in 2010–2011. AUGIB was defined as haematemesis or coffee ground vomiting leading to hospitalization or occurring in a hospitalized patient. Controls underwent endoscopy in 2010–2011, matched for sex/age. Rebleeding was defined as AUGIB >14 days up to five years after index bleeding. Overall, 303 patients had AUGIB, mean age 67 (±18), controls66 years (±19), females, 51 and 46%, respectively. The five-year rebleeding rate for AUGIB patients was 13% (95%CI 9–17%), higher than the rate of bleeding events in controls, 3% (95%CI 1–5%; log-rank <0.001), hazard ratio (HR) 6.0 (95%CI 2.4–15) when correcting for comorbidities, NSAID's, PPI's and antithrombotics. The mortality of AUGIB patients at end of follow-up was higher when compared to controls, 39% (95%CI 49–33%) vs. 26% (95%CI 30–21%), log-rank <0.001, comorbidity-adjusted HR 1.4 (1.1–1.9). A subanalysis of non-variceal AUGIB yielded similar results in regard to rebleeding and mortality rates. AUGIB patients were at 6-fold risk of rebleeding compared to bleeding events in controls at five years of follow-up. Five-year mortality was higher in AUGIB patients when compared to controls even when correcting for age and comorbidities, suggesting that an episode of AUGIB indicates serious frailty. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results